share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Heron Patrick J

SEC announcement ·  Mar 7 05:31
Summary by Futu AI
Patrick J Heron, associated with Arcutis Biotherapeutics, Inc. [ARQT], completed a purchase of 21,052 shares of common stock on March 4, 2024. The transaction was conducted in the open market at a price of $9.50 per share. Following this transaction, the total number of shares beneficially owned by Heron through direct and indirect holdings is 23,688. The indirect shares are held by Frazier Life Sciences VIII, L.P. This acquisition reflects a significant investment in the company, with the total value of the purchased shares amounting to approximately $199,994.
Patrick J Heron, associated with Arcutis Biotherapeutics, Inc. [ARQT], completed a purchase of 21,052 shares of common stock on March 4, 2024. The transaction was conducted in the open market at a price of $9.50 per share. Following this transaction, the total number of shares beneficially owned by Heron through direct and indirect holdings is 23,688. The indirect shares are held by Frazier Life Sciences VIII, L.P. This acquisition reflects a significant investment in the company, with the total value of the purchased shares amounting to approximately $199,994.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.